Literature DB >> 25269430

Lipid-based drug carriers for prodrugs to enhance drug delivery.

Jennica L Zaro1.   

Abstract

The combination of lipid drug delivery systems with prodrugs offers several advantages including improved pharmacokinetics, increased absorption, and facilitated targeting. Lipidization and use of lipid carriers can increase the pharmacological half-life of the drug, thus improving pharmacokinetics and allowing less frequent dosing. Lipids also offer advantages such as increased absorption through the intestines for oral drug absorption and to the CNS for brain delivery. Furthermore, the use of lipid delivery systems can enhance drug targeting. Endogenous proteins bind lipids in the blood and carry them to the liver to enable targeting of this organ. Drugs with significant side effects in the stomach can be specifically delivered to enterocytes by exploiting lipases for prodrug activation. Finally, lipids can be used to target the lymphatic system, thus bypassing the liver and avoiding first-pass metabolism. Lymphatic targeting is also important for antiviral drugs in the protection of B and T lymphocytes. In this review, both lipid-drug conjugates and lipid-based carriers will be discussed. An overview, including the chemistry and assembly of the systems, as well as examples from the clinic and in development, will be provided.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25269430      PMCID: PMC4287280          DOI: 10.1208/s12248-014-9670-z

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  82 in total

1.  Antitumor activity of P-4055 (elaidic acid-cytarabine) compared to cytarabine in metastatic and s.c. human tumor xenograft models.

Authors:  K Breistøl; J Balzarini; M L Sandvold; F Myhren; M Martinsen; E De Clercq; O Fodstad
Journal:  Cancer Res       Date:  1999-06-15       Impact factor: 12.701

2.  Engineering prolonged-acting prodrugs employing an albumin-binding probe that undergoes slow hydrolysis at physiological conditions.

Authors:  K Sasson; Y Marcus; V Lev-Goldman; S Rubinraut; M Fridkin; Y Shechter
Journal:  J Control Release       Date:  2009-10-30       Impact factor: 9.776

3.  Preparation of a complex of dexamethasone palmitate-low density lipoprotein and its effect on foam cell formation of murine peritoneal macrophages.

Authors:  Y Tauchi; M Takase; I Zushida; S Chono; J Sato; K Ito; K Morimoto
Journal:  J Pharm Sci       Date:  1999-07       Impact factor: 3.534

4.  Cell specific cytotoxicity and structure-activity relationship of lipophilic 1-B-D-arabinofuranosylcytosine (ara-C) derivatives.

Authors:  G J Peters; D A Voorn; C M Kuiper; C L van der Wilt; P Noordhuis; K Smid; F Myhren; M Sandvold; H R Hendriks
Journal:  Nucleosides Nucleotides       Date:  1999 Apr-May

5.  In vitro anti-human immunodeficiency virus and anti-hepatitis B virus activities and pharmacokinetic properties of heterodinucleoside phosphates containing AZT or ddC.

Authors:  P A Peghini; R Zahner; H Kuster; H Schott; R A Schwendener
Journal:  Antivir Chem Chemother       Date:  1998-03

6.  A new non-viral DNA delivery vector: the terplex system.

Authors:  J S Kim; B I Kim; A Maruyama; T Akaike; S W Kim
Journal:  J Control Release       Date:  1998-04-30       Impact factor: 9.776

7.  Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing mice.

Authors:  M S Newman; G T Colbern; P K Working; C Engbers; M A Amantea
Journal:  Cancer Chemother Pharmacol       Date:  1999       Impact factor: 3.333

8.  Low-density lipoprotein receptor-mediated delivery of a lipophilic daunorubicin derivative to B16 tumours in mice using apolipoprotein E-enriched liposomes.

Authors:  A J Versluis; P C Rensen; E T Rump; T J Van Berkel; M K Bijsterbosch
Journal:  Br J Cancer       Date:  1998-12       Impact factor: 7.640

9.  Low density lipoprotein and liposome mediated uptake and cytotoxic effect of N4-octadecyl-1-beta-D-arabinofuranosylcytosine in Daudi lymphoma cells.

Authors:  S K Koller-Lucae; H Schott; R A Schwendener
Journal:  Br J Cancer       Date:  1999-07       Impact factor: 7.640

Review 10.  Intestinal lymphatic transport for drug delivery.

Authors:  Jaime A Yáñez; Stephen W J Wang; Ian W Knemeyer; Mark A Wirth; Kevin B Alton
Journal:  Adv Drug Deliv Rev       Date:  2011-06-13       Impact factor: 15.470

View more
  12 in total

Review 1.  Lipid-Drug Conjugate for Enhancing Drug Delivery.

Authors:  Danielle Irby; Chengan Du; Feng Li
Journal:  Mol Pharm       Date:  2017-01-24       Impact factor: 4.939

Review 2.  Poly(amido amine) dendrimers in oral delivery.

Authors:  Venkata K Yellepeddi; Hamidreza Ghandehari
Journal:  Tissue Barriers       Date:  2016-04-06

3.  Preparation and evaluation of cefuroxime axetil gastro-retentive floating drug delivery system via hot melt extrusion technology.

Authors:  Rahul Lalge; Priyanka Thipsay; Vijay Kumar Shankar; Abhijeet Maurya; Manjeet Pimparade; Suresh Bandari; Feng Zhang; S Narasimha Murthy; Michael A Repka
Journal:  Int J Pharm       Date:  2019-06-08       Impact factor: 5.875

Review 4.  Lipophilic Conjugates of Drugs: A Tool to Improve Drug Pharmacokinetic and Therapeutic Profiles.

Authors:  Sifei Han; Lianghe Mei; Tim Quach; Chris Porter; Natalie Trevaskis
Journal:  Pharm Res       Date:  2021-08-31       Impact factor: 4.200

5.  Multifunctional Lipid Bilayer Nanocarriers for Cancer Immunotherapy in Heterogeneous Tumor Microenvironments, Combining Immunogenic Cell Death Stimuli with Immune Modulatory Drugs.

Authors:  André E Nel; Kuo-Ching Mei; Yu-Pei Liao; Xiangsheng Liu
Journal:  ACS Nano       Date:  2022-03-29       Impact factor: 18.027

6.  Therapeutically reprogrammed nutrient signalling enhances nanoparticulate albumin bound drug uptake and efficacy in KRAS-mutant cancer.

Authors:  Ran Li; Thomas S C Ng; Stephanie J Wang; Mark Prytyskach; Christopher B Rodell; Hannes Mikula; Rainer H Kohler; Michelle A Garlin; Douglas A Lauffenburger; Sareh Parangi; Daniela M Dinulescu; Nabeel Bardeesy; Ralph Weissleder; Miles A Miller
Journal:  Nat Nanotechnol       Date:  2021-05-06       Impact factor: 40.523

7.  Synthesis and Characterization of a New Bivalent Ligand Combining Caffeine and Docosahexaenoic Acid.

Authors:  Víctor Fernández-Dueñas; Jhonny Azuaje; Xavier Morató; Begoña Cordobilla; Joan Carles Domingo; Eddy Sotelo; Francisco Ciruela
Journal:  Molecules       Date:  2017-02-27       Impact factor: 4.411

8.  Molecular Modeling-Guided Design of Phospholipid-Based Prodrugs.

Authors:  Milica Markovic; Shimon Ben-Shabat; Shahar Keinan; Aaron Aponick; Ellen M Zimmermann; Arik Dahan
Journal:  Int J Mol Sci       Date:  2019-05-05       Impact factor: 5.923

9.  Phospholipid prodrug conjugates of insoluble chemotherapeutic agents for ultrasound targeted drug delivery.

Authors:  Mendi G Márquez; Rachel Dotson; Sally Pias; Liliya V Frolova; Michaelann S Tartis
Journal:  Nanotheranostics       Date:  2020-01-01

Review 10.  Small Molecule Radiopharmaceuticals - A Review of Current Approaches.

Authors:  Shubhra Chaturvedi; Anil K Mishra
Journal:  Front Med (Lausanne)       Date:  2016-02-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.